Revenue growth accelerated in SS&C?s fourth quarter, growing 7% on an organic basis, translating to about 6% organic growth for the full year. Topline outperformance was underpinned by strength in the company?s GlobeOps and Global Investor Distributions Solutions (GIDS) businesses, which benefitted from new business wins and growth in non-transfer agency services over the period. The company?s health care business also turned a corner, growing about 9% in the fourth quarter, supported by a number of sizable license deals that closed in the period as well two larger deals that were pushed from the third quarter. On the profitability side, SS&C continues to generate high levels of cash flow (about $1.4 billion generated from operating activities in fiscal 2024), with